Detailed narrative
PERFORMA Phase 3 MASH Trial Initiation and Design
Altimmune initiated the global PERFORMA Phase 3 trial for MASH, enrolling patients just three months after securing funding. The trial will span approximately 300 sites, with one-third in the U.S. and two-thirds internationally. Management expressed confidence in efficient enrollment, aiming for the lower end of an 18-24 month timeline, leveraging strong site relationships and the AIM-MASH Assist technology to reduce screen failures and improve consistency in pathology readings. The trial allows GLP-1 use at anti-diabetic doses but excludes resmetirom to protect the primary endpoint.
RECLAIM Phase 2 AUD Data Highlights Pemvidutide's Potential
The RECLAIM Phase 2 trial in Alcohol Use Disorder (AUD) reported strongly positive top-line data, meeting its primary endpoint with a statistically significant reduction of 1.45 heavy drinking days per week for pemvidutide 2.4 mg versus placebo. Key secondary endpoints, both recognized by the FDA as registrational, were also met: a 2-level reduction in WHO Risk Drinking Levels (achieved by two-thirds of pemvi patients) and a significant increase in 0 heavy drinking days (achieved by more than twice the number of pemvi patients). The trial also showed a 9.1% body weight reduction and encouraging FIB-4 improvement in patients with elevated baseline levels.
Pemvidutide's Differentiated Profile in Liver Diseases
Management emphasized pemvidutide's balanced 1:1 glucagon and GLP-1 agonism as a key differentiator, particularly for its potential direct effects on the liver. This dual mechanism is believed to address the totality of disease in AUD and ALD patients by reducing alcohol cravings while also providing liver benefits. This positions pemvidutide uniquely against other GLP-1 therapies, especially for higher-risk patients who often present with existing liver impairment.
Significant Unmet Need and Market Opportunity in AUD
The AUD market represents a considerable untapped opportunity, with approximately 12 million U.S. adults suffering from moderate to severe AUD, a population highly susceptible to liver damage. Despite significant health consequences, only 10% of AUD patients are diagnosed, and only one in four receives drug therapy. Altimmune believes pemvidutide's efficacy and potential liver benefits could disrupt this stagnant market, setting new expectations for drug therapy and increasing diagnosis rates, potentially driven by increased alcohol screening and PEth testing among liver specialists.
RESTORE Phase 2 ALD Trial Progress and Protocol Amendment
Enrollment for the RESTORE Phase 2 trial in Alcoholic Liver Disease (ALD) has been completed, with top-line data expected in the second half of 2027. The trial protocol was amended to allow for a hierarchical assessment of liver stiffness measurements (LSM) at week 48, followed by week 24. This change aims to more fully demonstrate pemvidutide's long-term liver benefits, aligning with the company's strategy to focus on higher-risk patients and differentiate the drug based on its liver impact.
Financial Strength and Non-Dilutive Funding Strategy
Altimmune reported a strengthened financial position with $519 million in cash as of June 30, 2026, following a $225 million follow-on offering in April. This provides an operating cash runway through the MASH Phase 3 52-week data readout in 2029. For the potential AUD Phase 3 trial, the company's preference is to secure non-dilutive funding, exploring options such as royalties, debt, or strategic partnerships, rather than relying on further equity dilution.